4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 33 Issue 6
Nov.  2019
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Supplements
Zhu Ping, Shan Xia, Liu Jinhui, Zhou Xin, Zhang Huo, Wang Tongshan, Wu Jianqing, Zhu Wei, Liu Ping. miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5[J]. The Journal of Biomedical Research, 2019, 33(6): 382-390. DOI: 10.7555/JBR.33.20180078
Citation: Zhu Ping, Shan Xia, Liu Jinhui, Zhou Xin, Zhang Huo, Wang Tongshan, Wu Jianqing, Zhu Wei, Liu Ping. miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5[J]. The Journal of Biomedical Research, 2019, 33(6): 382-390. DOI: 10.7555/JBR.33.20180078
shu

miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5

  • 1.

    Jiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics

  • 2.

    Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

  • 3.

    Department of Respiration, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China

  • 4.

    Department of Obstetrics and Gynecology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

  • 5.

    Department of Oncology, the Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, Jiangsu 215000, China

More Information
  • Corresponding author:

    Jianqing Wu, Jiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China. Tel: +86-25-68136930, E-mail: jwuny@njmu.edu.cn

    Wei Zhu and Ping Liu, Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029,China. Tel: +86-25-68136930, E-mails: zhuwei@njmu.edu.cnand liupinga28@163.com

  • Received Date: August 16, 2018
  • Revised Date: May 13, 2019
  • Accepted Date: June 03, 2019
  • Available Online: August 14, 2019
    Graphical Abstract
    • Abstract
  • Many evidences showed that drug resistance of gastric cancer cells could be regulated by the abnormal expression of microRNAs (miRNAs), a post-transcriptional regulator of gene expression. Thus, we investigated the role of miR-3622b-5p in the development of cisplatin (DDP) resistance in human gastric cancer cell lines. A set of biochemical assays were used to elucidate the mechanism by which miR-3622b-5p regulates drug resistance in cancer cells. The expression of miR-3622b-5p was measured by quantitative real-time PCR and showed that miR-3622b-5p was significantly downregulated in the plasma of patients with acquired drug resistance to platinum-based chemotherapy for gastric cancer. miR-3622b-5p was also found significantly downregulated in DDP-resistant gastric cancer cell line SGC7901/DDP, compared with the parental SGC7901 cells. An in vitro drug sensitivity assay showed that overexpression of miR-3622b-5p sensitized SGC7901/DDP cells to DDP. The luciferase activity of reporters constructed by BIRC5 3′-untranslated regions in SGC7901/DDP cells suggested that BIRC5 was target gene of miR-3622b-5p. Ecpotic miR-3622b-5p expression in SGC7901/DDP cells significantly repressed the expression of the BIRC5 and sensitized the cells to DDP-induced apoptosis. By contrast, treatment with miR-3622b-5p inhibitor increased the protein expression of BIRC5 and led to a lower proportion of apoptotic cells in the SGC7901 cells. In conclusion, our findings suggest that miR-3622b-5p regulates DDP resistance of human gastric cancer cells at least in part by repressing the expression of BIRC5. Altering miR-3622b-5p expression may be a potential therapeutic strategy for the treatment of chemoresistance in gastric cancer in the future.
    • FullText(HTML)
    • References (31)
  • [1]
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359–E386. doi: 10.1002/ijc.29210
    [2]
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11–20. doi: 10.1056/NEJMoa055531
    [3]
    Hwang JH. Understanding gastric cancer risk factors: we need to close the gap[J]. Gut Liver, 2018, 12(1): 1–2. doi: 10.5009/gnl17503
    [4]
    Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843–854. doi: 10.1016/0092-8674(93)90529-Y
    [5]
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281–297. doi: 10.1016/S0092-8674(04)00045-5
    [6]
    Zhao HN, Yu XT, Ding YF, et al. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2[J]. Oncotarget, 2016, 7(33): 53254–53268.
    [7]
    Wang L, Chen Y, Jiang Y, et al. MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4[J]. BMC Cancer, 2018, 18(1): 631. doi: 10.1186/s12885-018-4460-0
    [8]
    Huang LM, Hu CQ, Cao H, et al. MicroRNA-29c increases the chemosensitivity of pancreatic cancer cells by inhibiting USP22 mediated autophagy[J]. Cell Physiol Biochem, 2018, 47(2): 747–758. doi: 10.1159/000490027
    [9]
    Wang M, Cai WR, Meng R, et al. miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin[J]. Biochem Biophys Res Commun, 2018, 501(1): 48–54. doi: 10.1016/j.bbrc.2018.04.129
    [10]
    Lu MJ, Wang TS, He MF, et al. Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer[J]. Oncotarget, 2017, 8(14): 23008–23019.
    [11]
    Qiu TZ, Zhou X, Wang J, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer[J]. FEBS Lett, 2014, 588(7): 1168–1177. doi: 10.1016/j.febslet.2014.02.054
    [12]
    Zhao DS, Chen Y, Jiang H, et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure[J]. Cardiovasc Pathol, 2013, 22(6): 444–450. doi: 10.1016/j.carpath.2013.04.001
    [13]
    Zhou X, Zhu W, Li H, et al. Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis[J]. Sci Rep, 2015, 5: 11251. doi: 10.1038/srep11251
    [14]
    Zhu W, Shan X, Wang TS, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines[J]. Int J Cancer, 2010, 127(11): 2520–2529. doi: 10.1002/ijc.25260
    [15]
    Zhu W, Xu HG, Zhu DX, et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP[J]. Cancer Chemother Pharmacol, 2012, 69(3): 723–731. doi: 10.1007/s00280-011-1752-3
    [16]
    Xia L, Zhang DX, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells[J]. Int J Cancer, 2008, 123(2): 372–379. doi: 10.1002/ijc.23501
    [17]
    Zhu DX, Zhu W, Fang C, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes[J]. Carcinogenesis, 2012, 33(7): 1294–1301. doi: 10.1093/carcin/bgs179
    [18]
    Holohan C, van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm[J]. Nat Rev Cancer, 2013, 13(10): 714–726. doi: 10.1038/nrc3599
    [19]
    Hayes JD, Wolf CR. Molecular mechanisms of drug resistance[J]. Biochem J, 1990, 272(2): 281–295. doi: 10.1042/bj2720281
    [20]
    Sharma SV, Lee DY, Li BH, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations[J]. Cell, 2010, 141(1): 69–80. doi: 10.1016/j.cell.2010.02.027
    [21]
    Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs[J]. Drug Resist Updat, 2007, 10(1–2): 59–67.
    [22]
    Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy[J]. Nat Rev Cancer, 2008, 8(3): 193–204. doi: 10.1038/nrc2342
    [23]
    Selvakumaran M, Pisarcik DA, Bao RD, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines[J]. Cancer Res, 2003, 63(6): 1311–1316.
    [24]
    Liu HN, Peng Q, Yang G, et al. miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2[J]. Arch Med Sci, 2018, 14(4): 745–751.
    [25]
    Gao JL, Wu N, Liu XH, et al. MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1[J]. Exp Ther Med, 2018, 15(6): 5205–5214.
    [26]
    Feng Q, He P, Wang Y. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer[J]. Gene, 2018, 658: 152–158. doi: 10.1016/j.gene.2018.03.013
    [27]
    Chen X, Duan N, Zhang CG, et al. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies[J]. J Cancer, 2016, 7(3): 314–323. doi: 10.7150/jca.13332
    [28]
    Xiong CH, Liu HP, Chen ZX, et al. Prognostic role of survivin in renal cell carcinoma: a system review and meta-analysis[J]. Eur J Intern Med, 2016, 33: 102–107. doi: 10.1016/j.ejim.2016.06.009
    [29]
    Peery RC, Liu JY, Zhang JT. Targeting survivin for therapeutic discovery: past, present, and future promises[J]. Drug Discov Today, 2017, 22(10): 1466–1477. doi: 10.1016/j.drudis.2017.05.009
    [30]
    Nabilsi NH, Broaddus RR, Loose DS. DNA methylation inhibits p53-mediated survivin repression[J]. Oncogene, 2009, 28(19): 2046–2050. doi: 10.1038/onc.2009.62
    [31]
    Huang JC, Lyu H, Wang JX, et al. MicroRNA regulation and therapeutic targeting of survivin in cancer[J]. Am J Cancer Res, 2015, 5(1): 20–31.
    • Related Articles

  • Related Articles

    [1]Pavan Kumar Dhanyamraju. Drug resistance mechanisms in cancers: Execution of pro-survival strategies[J]. The Journal of Biomedical Research, 2024, 38(2): 95-121. DOI: 10.7555/JBR.37.20230248
    [2]Juan Zhou, Yiran Xu, Luyao Wang, Yu Cong, Ke Huang, Xinxing Pan, Guangquan Liu, Wenqu Li, Chenchen Dai, Pengfei Xu, Xuemei Jia. LncRNA IDH1-AS1 sponges miR-518c-5p to suppress proliferation of epithelial ovarian cancer cell by targeting RMB47[J]. The Journal of Biomedical Research, 2024, 38(1): 51-65. DOI: 10.7555/JBR.37.20230097
    [3]Liting Lv, Xin Hua, Jiaxin Liu, Sutong Zhan, Qianqian Zhang, Xiao Liang, Jian Feng, Yong Song. Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240045
    [4]Yue Xiao, Yue Peng, Chi Zhang, Wei Liu, Kehan Wang, Jing Li. hucMSC-derived exosomes protect ovarian reserve and restore ovarian function in cisplatin treated mice[J]. The Journal of Biomedical Research, 2023, 37(5): 382-393. DOI: 10.7555/JBR.36.20220166
    [5]Haozhe Xu, Yiming Zhou, Jing Guo, Tao Ling, Yujie Xu, Ting Zhao, Chuanxin Shi, Zhongping Su, Qiang You. Elevated extracellular calcium ions accelerate the proliferation and migration of HepG2 cells and decrease cisplatin sensitivity[J]. The Journal of Biomedical Research, 2023, 37(5): 340-354. DOI: 10.7555/JBR.37.20230067
    [6]Xiao Shi, Xinxin Si, Ershao Zhang, Ruochen Zang, Nan Yang, He Cheng, Zhihong Zhang, Beijing Pan, Yujie Sun. Paclitaxel-induced stress granules increase LINE-1 mRNA stability to promote drug resistance in breast cancer cells[J]. The Journal of Biomedical Research, 2021, 35(6): 411-424. DOI: 10.7555/JBR.35.20210105
    [7]Min-Young Kim, Woon-Dong Cho, Kwon Pyo Hong, Da Bin Choi, Jeong won Hong, Soseul Kim, Yoo Ri Moon, Seung-Myoung Son, Ok-Jun Lee, Ho-Chang Lee, Hyung Geun Song. Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells[J]. The Journal of Biomedical Research, 2016, 30(3): 217-224. DOI: 10.7555/JBR.30.2016K0005
    [8]Xiaoyan Wang, Guozhu Wang, Yi Zhao, Xiaoan Liu, Qiang Ding, Jingping Shi, Yin Ding, Shui Wang. STAT3 mediates resistance of CD44+CD24-/low breast cancer stem cells to tamoxifen in vitro[J]. The Journal of Biomedical Research, 2012, 26(5): 325-335. DOI: 10.7555/JBR.26.20110050
    [9]Li Liu, Qi Chen, Rensheng Lai, Xiaobin Wu, Xiaoyu Wu, Fukun Liu, Guohua Xu, Yong Ji. Elevated expression of mature miR-21 and miR-155 in cancerous gastric tissues from Chinese patients with gastric cancer[J]. The Journal of Biomedical Research, 2010, 24(3): 187-197.
    [10]Daozhen Chen, Qiusha Tang, Wenqun Xue, Jingying Xiang, Li Zhang, Xinru Wang. The preparation and characterization of folate-conjugated human serum albumin magnetic cisplatin nanoparticles[J]. The Journal of Biomedical Research, 2010, 24(1): 26-32.
    • Supplements (1)

  • Other Related Supplements

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3484) PDF downloads (72) Cited by()
    Related

    ©2023 by the Editorial Department of the Journals of Nanjing Medical University. All rights reserved.   苏ICP备05071376号-5

    Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail: info@rhhz.net  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return